Smiljana Ristic

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone
    S Ristic
    Novartis Pharma, Basel, Switzerland
    Diabet Med 23:757-62. 2006
  2. ncbi Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response
    S Ristic
    Novartis Pharma, Basel, Switzerland
    Diabetes Obes Metab 7:692-8. 2005
  3. ncbi Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes
    Smiljana Ristic
    Clinical Research and Development, Novartis Pharma AG, Basel, Switzerland
    Drugs Today (Barc) 42:519-31. 2006
  4. ncbi Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results
    S Ristic
    Novartis Pharma, Basel, Switzerland
    Diabetes Obes Metab 9:506-11. 2007
  5. ncbi Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus
    Smiljana Ristic
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Diabetes Technol Ther 5:57-66. 2003
  6. ncbi Acceptability of a reusable insulin pen, HumaPen Ergo, by patients with type 1 and type 2 diabetes
    Smiljana Ristic
    Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK
    Curr Med Res Opin 18:68-71. 2002

Detail Information

Publications6

  1. ncbi Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone
    S Ristic
    Novartis Pharma, Basel, Switzerland
    Diabet Med 23:757-62. 2006
    ..To compare the effects of nateglinide plus metformin with gliclazide plus metformin on glycaemic control in patients with Type 2 diabetes...
  2. ncbi Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response
    S Ristic
    Novartis Pharma, Basel, Switzerland
    Diabetes Obes Metab 7:692-8. 2005
    ..This study was designed to establish a dose of the DPP-4-inhibitor vildagliptin (LAF237) that was effective in reducing HbA1c levels and was safe and well tolerated in patients with type 2 diabetes...
  3. ncbi Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes
    Smiljana Ristic
    Clinical Research and Development, Novartis Pharma AG, Basel, Switzerland
    Drugs Today (Barc) 42:519-31. 2006
    ..Vildagliptin did not cause any clinically relevant changes in safety and was well tolerated. Therefore, further studies are being carried out on vildagliptin to assess long-term efficacy and safety in patients with type 2 diabetes...
  4. ncbi Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results
    S Ristic
    Novartis Pharma, Basel, Switzerland
    Diabetes Obes Metab 9:506-11. 2007
    ..To compare long-term efficacy and safety of nateglinide plus metformin with those of gliclazide plus metformin in patients with type 2 diabetes not adequately controlled with metformin monotherapy...
  5. ncbi Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus
    Smiljana Ristic
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Diabetes Technol Ther 5:57-66. 2003
    ..The better overall metabolic control with rapid-acting insulin analogs was not accompanied by any increased risk for hypoglycemia...
  6. ncbi Acceptability of a reusable insulin pen, HumaPen Ergo, by patients with type 1 and type 2 diabetes
    Smiljana Ristic
    Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK
    Curr Med Res Opin 18:68-71. 2002
    ..The HumaPen Ergo was well accepted by both patients and health-care professionals and provides an important tool to combat the trauma and inconvenience associated with insulin self-injection...